Results 1 to 10 of about 283,429 (68)

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Circulation Research, 2023
: Pulmonary arterial hypertension forms the first and most severe of the 5 categories of pulmonary hypertension. Disease pathogenesis is driven by progressive remodeling of peripheral pulmonary arteries, caused by the excessive proliferation of vascular ...
Iona Cuthbertson, N. Morrell, P. Caruso
semanticscholar   +1 more source

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2021
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, R. Souza, A. Waxman, Pilar Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. Barnes, P. Linde, J. de Oliveira Pena, D. Badesch   +17 more
semanticscholar   +1 more source

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

European Respiratory Journal, 2022
Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, Rogério Souza, A. Waxman, H. Ghofrani, Pilar Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. de Oliveira Pena, D. Badesch   +16 more
semanticscholar   +1 more source

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

European Respiratory Journal, 2021
Background Risk stratification plays an essential role in the management of patients with pulmonary arterial hypertension (PAH). The current European guidelines propose a three-stratum model to categorise risk as low, intermediate or high, based on the ...
M. Hoeper, C. Pausch, K. Olsson, D. Huscher, D. Pittrow, E. Grünig, G. Staehler, C. Vizza, H. Gall, O. Distler, C. Opitz, J. Gibbs, M. Delcroix, H. Ghofrani, D. Park, R. Ewert, H. Kaemmerer, H. Kabitz, D. Skowasch, J. Behr, K. Milger, M. Halank, H. Wilkens, H. Seyfarth, M. Held, D. Dumitrescu, I. Tsangaris, A. Vonk-Noordegraaf, S. Ulrich, H. Klose, M. Claussen, T. Lange, S. Rosenkranz   +32 more
semanticscholar   +1 more source

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

European Respiratory Journal, 2021
Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and development of plexiform lesions.
C. Evans, N. Cober, Z. Dai, D. Stewart, You-yang Zhao   +4 more
semanticscholar   +1 more source

Molecular Pathways in Pulmonary Arterial Hypertension

International Journal of Molecular Sciences, 2022
Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and
Aangi J Shah, Mounica Vorla, D. Kalra
semanticscholar   +1 more source

The physiological basis of pulmonary arterial hypertension

European Respiratory Journal, 2021
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) failure.
R. Naeije, M. Richter, L. Rubin
semanticscholar   +1 more source

ERK/Drp1‐dependent mitochondrial fission contributes to HMGB1‐induced autophagy in pulmonary arterial hypertension

Cell Proliferation, 2021
High‐mobility group box‐1 (HMGB1) and aberrant mitochondrial fission mediated by excessive activation of GTPase dynamin‐related protein 1 (Drp1) have been found to be elevated in patients with pulmonary arterial hypertension (PAH) and critically ...
Wei Feng, Jian Wang, Xin Yan, Qianqian Zhang, Limin Chai, Qingting Wang, Wenhua Shi, Yuqian Chen, Jin Liu, Zhan Qu, Shaojun Li, Xinming Xie, Manxiang Li   +12 more
semanticscholar   +1 more source

Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension

HYPERTENSION, 2020
Supplemental Digital Content is available in the text. Pulmonary arterial hypertension (PAH) is considered a disease of the pulmonary vasculature. Limited progress has been made in preventing or arresting progression of PAH despite extensive efforts. Our
Seungbum Kim, Katya Rigatto, M. B. Gazzana, M. Knorst, E. Richards, C. Pepine, M. Raizada   +6 more
semanticscholar   +1 more source

Pulmonary arterial hypertension

Orphanet Journal of Rare Diseases, 2013
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimately death if untreated. The first classification of PH was proposed in 1973. In 2008, the fourth World Symposium on PH held in Dana Point
D. Montani, S. Günther, P. Dorfmüller, F. Perros, B. Girerd, G. Garcia, X. Jaïs, L. Savale, Élise Artaud-Macari, L. Price, M. Humbert, G. Simonneau, O. Sitbon   +12 more
semanticscholar   +1 more source